ClinicalTrials.gg
RecruitingNCT05163288Updated Apr 3, 2026

A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C

A Phase 3 interventional study of N-Acetyl-L-Leucine and Placebo in Niemann-Pick Disease, Type C, sponsored by IntraBio Inc. Recruiting at 14 sites in 8 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by IntraBio Inc · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Niemann-Pick Disease, Type C with a site in Germany — 3 open to participants now, 4 under way, 4 of them phase 3. Niemann-Pick Disease, Type C · Germany.

Started
2022
the only one that year
Phase 3
4 of 10
3 open now
Registered
8th of 10
by date
Lead sponsor
2 of 10
IntraBio Inc

Among the 10 studies in Niemann-Pick Disease, Type C with a site in Germany, this one is the only one that started in 2022, is one of 4 in phase 3, and was the 8th registered.

Niemann-Pick Disease, Type C

37 studies on the registry are indexed under Niemann-Pick Disease, Type C; 8 are open to participants now.

Browse Niemann-Pick Disease, Type C studies →

Open to participants now

3 of the 10 studies in Niemann-Pick Disease, Type C with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 5 Niemann-Pick Disease, Type C studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Niemann-Pick Disease, Type C with a site in Germany, or all of them as a file.
02

Study summary

A pivotal, randomized, double-blind, placebo controlled, multi-center therapeutic study for patients age 4 and older with a confirmed diagnosis of Niemann Pick disease type C (NPC). The objective of this study is to evaluate the safety, tolerability and efficacy of N-acetyl-L-leucine (IB1001) compared to standard of care.

Following this randomized, double-blind, placebo-controlled "Parent Study", an extension phase is conducted for (1) patients who completed the "Parent Study" and (2) patients who are enrolled directly into the Extension Phase. Currently, the Extension Phase provides patients with 3 years of open-label treatment.

Read the detailed description

This is a multinational, randomized, placebo-controlled, double-blinded, cross-over Phase III study that will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) versus Placebo for the treatment of Niemann-Pick type C disease (NPC).

Patients will be assessed during three study periods: a baseline period (approximately 2-weeks), after which they will be randomized (1:1) to receive treatment with IB1001 or Placebo for approximately 12-weeks during the first intervention period ("Period I"). Following Period I, patients will crossover to receive the opposite treatment (IB1001 or Placebo) for approximately 12-weeks during a second intervention period ("Period II).

Patients will be assessed twice during each study period. Patients who have participated in the study may be offered the opportunity to roll over into an Extension Phase, which is planned to allow patients to have further access to IB1001.

03

Conditions studied

  • Niemann-Pick Disease, Type C
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written signed by the patient and/or their legal representative/ parent/ impartial witness
  2. Male or female aged ≥4 years with a confirmed genetic diagnosis of NPC at the time of signing informed consent.
  3. Females of , defined as a premenopausal female capable of becoming pregnant, will be included if they are either sexually inactive (sexually abstinent for 14 days prior to the first dose and confirm to continue through 28 days after the last dose) or using one of the following highly effective (i.e. results in \<1% failure rate when used consistently and correctly) 14 days prior to the first dose continuing through 28 days after the last dose:

    1. intrauterine device (IUD);
    2. surgical sterilization of the partner (vasectomy for 6 months minimum);
    3. combined (estrogen or progestogen containing) hormonal contraception associated with the inhibition of ovulation (either oral, intravaginal, or transdermal);
    4. progestogen only hormonal contraception associated with the inhibition of ovulation (either oral, injectable, or implantable);
    5. intrauterine hormone releasing system (IUS);
    6. bilateral tubal occlusion.
  4. Females of non-childbearing potential who have undergone one of the following sterilization procedures at least 6 months prior to the first dose:

    1. hysteroscopic sterilization;
    2. bilateral tubal ligation or bilateral salpingectomy;
    3. hysterectomy;
    4. bilateral oophorectomy; OR be with amenorrhea for at least 1 year prior to the first dose and follicle stimulating hormone (FSH) serum levels consistent with postmenopausal status. FSH analysis for postmenopausal women will be done at screening. FSH levels should be in the postmenopausal range as determined by the central laboratory.
  5. Non-vasectomized male patient agrees to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study medication and the female partner agrees to comply with inclusion criteria 3 or 4.

    For a vasectomized male who has had his vasectomy 6 months or more prior to study start, it is required that they use a condom during sexual intercourse. A male who has been vasectomized less than 6 months prior to study start must follow the same restrictions as a non-vasectomized male.

  6. If male, patient agrees not to donate sperm from the first dose until 90 days after their last dose.
  7. Patients must fall within:

    a) A SARA score of 7 ≤ X ≤ 34 points (out of 40) AND b) Either: i. Within the 2-7 range (0-8 range) of the Gait subtest of the SARA scale OR ii. Be able to perform the 9-Hole Peg Test with Dominant Hand (9HPT-D) (SCAFI subtest) in 20 ≤ X ≤150 seconds.

  8. Weight ≥15 kg at screening.
  9. Patients are willing to disclose their existing medications/therapies for (the symptoms) of NPC including those on the prohibited medication list. Non-prohibited medications/therapies (authorized medicines for NPC [e.g. miglustat], speech therapy, and physiotherapy) are permitted provided:

    1. The Investigator does not believe the medication/therapy will interfere with the study protocol/results
    2. Patients have been on a stable dose/duration and type of therapy for at least 42 days before Visit 1 (Baseline 1)
    3. Patients are willing to maintain a stable dose/do not change their therapy throughout the duration of the study.
  10. An understanding of the implications of study participation, provided in the written patient information and informed consent by patients or their legal representative/parent, and demonstrates a willingness to comply with instructions and attend required study visits (for children this criterion will also be assessed in parents or appointed guardians).

Exclusion criteria

Exclusion Criteria:

  1. Patients who are unable to consistently Patients who have any known or history of hypersensitivity to:

    1. Acetyl-Leucine (DL-, L-, D-) or derivatives.
    2. the IB1001 sachet (namely isomalt, hypromellose, and strawberry flavour).
    3. Excipients the placebo sachet (namely isomalt, hypromellose, strawberry flavour, citric acid, microcrystalline cellulose, lactose, denatonium benzoate).
  2. Simultaneous participation in another clinical study or participation in any clinical study involving administration of an medicinal product (IMP; 'study drug') for at least 42 days prior to Visit 1. At the discretion of the investigator, Medical Monitor, and Sponsor, the for specific IMPs may be longer based on the pharmacological activity and pharmacokinetics of the drug.
  3. Patients with a physical, cognitive, or psychiatric condition which, at the investigator's discretion and in consultation with the Medical Monitor and Sponsor (as applicable), may put the patient at risk, may confound the study results, or may interfere with the patient's participation in the clinical study, i.e. reliably perform study assessments.
  4. Known or persistent use, misuse, or dependency of medication, drugs, or alcohol.
  5. Current or planned pregnancy or women who are breastfeeding.
  6. Patients with severe vision or hearing impairment (that is not corrected by glasses or hearing aids) that, at the investigator's discretion, interferes with their ability to perform study assessments.
  7. Patients who have been diagnosed with arthritis or other musculoskeletal disorders affecting joints, muscles, ligaments, and/or nerves that by themselves affects patient's mobility and, at the investigator's discretion, interferes with their ability to perform study assessments.
  8. Patients unwilling and/or not able to undergo a 42 day period from any of the following prohibited medication prior to Visit 1 (Baseline 1) and remain without prohibited medication through Visit 6.

    1. N-Acetyl-DL-Leucine (e.g. Tanganil®);
    2. N-Acetyl-L-Leucine (prohibited if not provided as IMP in the IB1001-301 trial);
    3. Sulfasalazine;
    4. Rosuvastatin.

      -

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
53 participants (estimated)

Study arms

  • Experimental
    N-acetyl-L-leucine (IB1001)

    Oral administration (granule in a sachet for suspension in water, orange juice, or almond milk). Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day); patients \<13 will receive weight-tiered doses.

    Drug: N-Acetyl-L-Leucine

  • Placebo comparator
    Placebo comparator

    Oral administration (granule in a sachet for suspension in water, orange juice, or almond milk). Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day); patients \<13 will receive weight-tiered doses.

    Other: Placebo

Interventions

  • N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)

    Also known as: IB1001

  • OtherPlacebo

    Matching Placebo Sachet

06

What researchers measure

Primary outcomes

  1. Scale for the Assessment and Rating of Ataxia (all jurisdictions except US)

    Time frame: End of Period I (week 12) vs. End of Period 2 (week 24)

  2. Modified Scale for the Assessment and Rating of Ataxia (US only)

    Time frame: End of Period I (week 12) vs. End of Period 2 (week 24)

Secondary outcomes

  1. Spinocerebellar Ataxia Functional Index (SCAFI)

    Time frame: End of Period I (week 12) vs. End of Period 2 (week 24)

  2. Modified Disability Rating Scale

    Time frame: End of Period I (week 12) vs. End of Period 2 (week 24)

  3. Physician's / Caregiver's / Patient's Clinical Global Impressions (CGI)

    Time frame: End of Period I (week 12) vs. End of Period 2 (week 24)

  4. EuroQuol- 5 Dimension (EQ-5D) Quality of Life Scale

    Time frame: End of Period I (week 12) vs. End of Period 2 (week 24)

  5. Scale for the Assessment and Rating of Ataxia (US only)

    Time frame: End of Period I (week 12) vs. End of Period 2 (week 24)

Other outcomes

  1. Niemann-Pick disease type C Clinical Severity Scale (NPC-CSS)

    Time frame: End of Period I (week 12) vs. End of Period 2 (week 24)

  2. 5-Domain Niemann-Pick disease type C Clinical Severity Scale (NPC-CSS)

    Time frame: End of Period I (week 12) vs. End of Period 2 (week 24)

  3. Investigator's / Caregiver's / Patient's Clinical Global Impressions (CGI)

    Time frame: End of Period I (week 12) vs. End of Period 2 (week 24)

  4. Modified Scale for the Assessment and Rating of Ataxia (all jurisdictions except US)

    Time frame: End of Period I (week 12) vs. End of Period 2 (week 24)

07

Study locations

1 of 14 sites recruiting
08

References and documents

Publications

  • Bremova-Ertl T, Claassen J, Foltan T, Gascon-Bayarri J, Gissen P, Hahn A, Hassan A, Hennig A, Jones SA, Kolnikova M, Martakis K, Raethjen J, Ramaswami U, Sharma R, Schneider SA. Efficacy and safety of N-acetyl-L-leucine in Niemann-Pick disease type C. J Neurol. 2022 Mar;269(3):1651-1662. doi: 10.1007/s00415-021-10717-0. Epub 2021 Aug 13. PubMed 34387740 ↗
  • Kaya E, Smith DA, Smith C, Morris L, Bremova-Ertl T, Cortina-Borja M, Fineran P, Morten KJ, Poulton J, Boland B, Spencer J, Strupp M, Platt FM. Acetyl-leucine slows disease progression in lysosomal storage disorders. Brain Commun. 2020 Dec 20;3(1):fcaa148. doi: 10.1093/braincomms/fcaa148. eCollection 2021. PubMed 33738443 ↗
  • Cortina-Borja M, Te Vruchte D, Mengel E, Amraoui Y, Imrie J, Jones SA, I Dali C, Fineran P, Kirkegaard T, Runz H, Lachmann R, Bremova-Ertl T, Strupp M, Platt FM. Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials. Orphanet J Rare Dis. 2018 Aug 16;13(1):143. doi: 10.1186/s13023-018-0880-9. PubMed 30115089 ↗
  • Hendrickx N, Mentre F, Hamdan A, Karlsson MO, Hooker AC, Traschutz A, Gagnon C, Schule R, Synofzik M, Comets E; ARCA Study Group, EVIDENCE-RND consortium. Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models: a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA score. BMC Med Res Methodol. 2025 Jul 30;25(1):179. doi: 10.1186/s12874-025-02626-x. PubMed 40739200 ↗
  • Patterson MC, Ramaswami U, Donald A, Foltan T, Gautschi M, Gissen P, Hahn A, Jones SA, Kay R, Kolnikova M, Park J, Reichmannova S, Walterfang M, Wibawa P, Rohrbach M, Martakis K, Bremova-Ertl T. Disease-Modifying, Neuroprotective Effect of N-Acetyl-l-Leucine in Adult and Pediatric Patients With Niemann-Pick Disease Type C. Neurology. 2025 Jul;105(1):e213589. doi: 10.1212/WNL.0000000000213589. Epub 2025 Jun 13. PubMed 40513057 ↗
  • Bremova-Ertl T, Ramaswami U, Brands M, Foltan T, Gautschi M, Gissen P, Gowing F, Hahn A, Jones S, Kay R, Kolnikova M, Arash-Kaps L, Marquardt T, Mengel E, Park JH, Reichmannova S, Schneider SA, Sivananthan S, Walterfang M, Wibawa P, Strupp M, Martakis K. Trial of N-Acetyl-l-Leucine in Niemann-Pick Disease Type C. N Engl J Med. 2024 Feb 1;390(5):421-431. doi: 10.1056/NEJMoa2310151. PubMed 38294974 ↗

Individual participant data

Plan to share: No — The results of the study will be published within a reasonable timeframe of completion. Pseudonymised individual patient data may be available in these findings.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for Jun 2030, 95 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2021
First posted
Dec 20, 2021
StartActual
Jun 30, 2022
Primary completionEst.
Jun 12, 2030
CompletionEst.
Dec 2030
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05163288
Lead sponsor
IntraBio Inc
Responsible party
Sponsor
First posted
Dec 20, 2021
Start date
Jun 30, 2022
Primary completion
Jun 12, 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Apr 3, 2026

Study contacts

Michael Strupp, MD
Contact
mstrupp@intrabio.com
+44 8081 641283
Taylor Fields
Contact
tfields@intrabio.com
+44 8081 641283

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levacetylleucine

Start the discussion